AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Inclusion Criteria

• •Histologically confirmed primary CNS tumor
• •* Histologically benign brain tumors (e.g., low-grade glioma) allowed
• •* Histological requirement waived for intrinsic brain stem or diffuse optic pathway tumors, but must have clinical and/or radiographic evidence of progression
• •Recurrent, progressive, or refractory disease
• •Absolute neutrophil count \>= 1,000/mm\^3 (unsupported)
• •Platelet count \>= 75,000/mm\^3 (unsupported)
• •Creatinine =\< 1.5 times upper limit of normal (ULN) OR glomerular filtration rate \>= 70 mL/min
• •Bilirubin =\< 1.5 times ULN
• •ALT =\< 2.5 times ULN
• •Urine dipstick or urinalysis \< 1+ protein
• •Albumin \>= 3 g/dL
• •Karnofsky performance status (PS) 60-100% (\> 16 years of age) OR Lansky PS 60-100% (=\< 16 years of age)
• •Karnofsky/Lansky PS 70-100% for patients at increased risk for compromised LVEF
• •Hemoglobin \>= 8 g/dL (transfusion support allowed)
• •No overt renal, hepatic, cardiac, or pulmonary disease
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •QTc prolongation =\< 500 msec
• •No other significant ECG abnormality within the past 14 days
• •No clinically significant, unrelated, systemic illness, including serious infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that would preclude study participation
• •No uncontrolled hypertension
• •* Defined as systolic and diastolic BP \> 95th percentile for age (ages 1-17)
• •* Defined as BP \> 140/90 (ages 18 and older)
• •No New York Heart Association class III or IV disease and Karnofsky/Lansky PS \< 70
• •* Class II disease controlled with treatment and increased monitoring is allowed
• •Recovered from all prior therapy
• •No prior AZD2171
• •At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas)
• •More than 1 weeks since prior investigational or biologic agents
• •* If the investigational or biologic agent has a prolonged half-life (\> 48 hours), then these patients must be discussed with the study chair prior to registration
• •No concurrent drugs or biologics with proarrhythmic potential
• •More than 3 months since last fraction of craniospinal radiotherapy or total-body irradiation
• •More than 4 weeks since last fraction of focal irradiation to symptomatic metastatic sites
• •At least 6 months since prior allogeneic bone marrow transplantation
• •At least 3 months since prior autologous bone marrow or stem cell transplantation
• •At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa (2 weeks for pegfilgrastim)
• •No other concurrent investigational agents
• •Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for ≥ 1 week before study entry
• •No concurrent chemotherapy
• •No concurrent routine use of G-CSF, GM-CSF, or epoetin alfa
• •Able to swallow tablets
• •Any neurologic deficits must be stable for \>= 1 week
• •If the investigational or biologic agent has a prolonged half-life (\> 48 hours), then these patients must be discussed with the study chair prior to registration